

# Capital Management

Solvency II:  
optimising stock and flow


Chris Figeo, CFO

Goldman Sachs European Financials Conference  
6 June 2018 - Frankfurt



a.s.r.  
de nederlandse  
verzekering  
maatschappij  
voor alle  
verzekeringen

## a.s.r. at a glance



Founded in 1720; deeply rooted in Dutch society


# #3

Leading market positions and strong #3 overall

## α.s.r.



Multi-brand and multi-channel distribution; focus on intermediaries



Business mix by GWP  
€4.4bn 2016

3,500  
Employees(fte)



1,500,000  
Households (Retail customers and SME)

Value over volume  
key strategic principle

Organic & inorganic growth  
to enhance capital generation

# 2008

Nationalized; no state aid received

# 2016

successful IPO

# 2017

Privatization completed

## Disciplined execution and delivering on medium-term targets (communicated at IPO)

**Solvency II (SF)**

**196%\***

**>160%**  
medium-term target

**Operating return on equity**

**15.6%**

**Up to 12%**  
medium-term target

**S&P rating (insurance business)**

**Single A**

**Single A**  
medium-term target

**Combined ratio Non-life**

**95.1%**

**<97%**  
medium-term target

**Operating expenses**

**€ 584m**

absorbing cost base of acquisitions; on track for medium-term target

**Financial leverage**

**25.3%**

**<30%**  
medium-term target

\*Excluding a.s.r. Bank and after proposed dividend


# Strategy to create value for customer and shareholder



Meeting customers' needs



Excellence in pricing, underwriting and claims handling



Cost effectiveness



Solid financial framework

**Our principles drive value in our business portfolio**



Stable cash flows and value generating businesses




Robust and predictable back books




Business enhancement opportunities

# Strong and resilient balance sheet


**Solvency II composition (in %)**



**Financial flexibility (in €m)**




**Financial leverage (in %)**




**S&P leverage (in %)**

40% leverage to maintain A rating




**Debt maturity profile**




Potential call prefinanced



**Interest coverage ratio (IFRS, multiple)**




# Unencumbered access to pools of liquidity




\* Excluding a.s.r. Health

- Holding cash of € 463m at year-end 2017, safely above the year-end target of € 350m
- Total shareholder return of € 442m in 2017
- Strongly capitalised operating companies:
  - Strong track record of operating companies upstreaming cash
  - Remittance of operating companies exceeded OCC
  - Remittance of operating companies exceeded the net result after tax and hybrids
  - Low double leverage
- The a.s.r. policy is to maintain cash where it can yield, therefore a.s.r. will only upstream cash if applicable
- Other cash remittance consisted primarily of holding costs and hybrids costs

# Evolution of insurance metrics



# Quality of Capital: The next focus point



RT2/RT3 headroom is effectively a function of required capital including market risk

DTA's will consume RT3 space; eventually also reducing eligibility of RT2 capital

Upon decline of UT1, RT1 will move into RT2 category

**Ineligibility not a problem in "all is well scenario", but may become a serious issue in case of asset losses, interest rate increases etc.**

## Beware of the spiral accelerating effect; down is dangerous!



- Reduced capital requires de-risking, reducing future capital generation capacity

- Evaporation of vulnerable LACDT components

“Sudden” ineligibility of:

RT1 / RT3 due to negative market developments

RT2 / RT3 due to de-risking





- Capital enables generation of flow that creates future capital


- Excess returns continue to be realized

- Invest in value enhancing opportunities


# Indicators of “positive/negative spiral” potential



# Flow perspective: OCC & EOF accretion



# How to positively impact 'flow'



# Afterthought... themes for coming years

## Best estimate assumptions

- What assumptions in COR, cost level are embedded in your BEL? Especially in LT liabilities
- As time passes, are you meeting or matching these? Will you be able to outperform your BEL assumptions?

## Tiering and capital eligibility

- Under what scenario's will you face ineligible capital (RT2, RT3)?
- What if rates go up, create DTA's and diminish RT3 and RT2 space?
- If you'd take a Solvency II hit and have to de-risk, would that eliminate RT2 eligibility?

## Balance sheet metrics

- With IFRS 17 inevitable approaching, what metrics will you steer your balance sheet on going forward?
- Interest cover based on OCC? Financial leverage related to UFR-adjusted EOF?

## EOF growth

- Will (sustainable) growth in EOF become the relevant "next generation" metric?
- How does UFR unwind relate to risk margin release?

# Disclaimer

## Cautionary note regarding forward-looking statements

Certain of the statements contained herein are not historical facts, including, without limitation, certain statements made of future expectations and other forward-looking statements. These statements may be identified by words such as “expect”, “should”, “could”, “shall” and similar expressions.

ASR Nederland cautions that such forward-looking statements are qualified by certain risks and uncertainties that could cause actual results and events to differ materially from what is contemplated by the forward-looking statements.

Factors which could cause actual results to differ from these forward-looking statements may include, without limitation: general economic conditions; conditions in the markets in which ASR Nederland is engaged; changes in the performance of financial markets; behavior of customers, suppliers, investors, shareholders and competitors; technological developments; the implementation and execution of new ICT systems or outsourcing; changes in the availability of, and costs associated with, sources of liquidity as well as conditions in the credit markets generally; the frequency and severity of insured loss events; changes affecting mortality and morbidity levels and trends; changes in laws and regulations including without limitation Solvency II and IFRS; changes in the policies of governments and/or regulatory authorities; conclusions with regard to accounting assumptions

and methodologies; adverse developments in legal and other proceedings; risks related to mergers, acquisitions, and divestments and the other risks and uncertainties detailed in the Risk Factors section contained in recent public disclosures made by ASR Nederland. In addition, financial risks such as currency movements, interest rate fluctuations, liquidity, and credit risks could influence future results.

The foregoing list of factors should not be construed as exhaustive. Any forward-looking statements made by or on behalf of ASR Nederland speak only as of the date they are made and, except as required by applicable law, ASR Nederland disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Neither ASR Nederland nor any of its directors, officers, employees do make any representation, warranty or prediction that the results anticipated by such forward-looking statements will be achieved, and such forward-looking statements represent, in each case, only one of many possible scenarios and should not be viewed as the most likely or standard scenario. We qualify any and all of our forward-looking statements by these cautionary factors.

This document does not constitute an offer to sell, or a solicitation of an offer to buy, any securities.